|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
一项在选定晚期实体瘤受试者中评价ADRX-0706的Ia/b期研究
[Translation] A Phase Ia/b Study Evaluating ADRX-0706 in Selected Subjects with Advanced Solid Tumors
这是一个两部分的研究。1a期将包括ADRX-0706的剂量递增,以评估选定晚期实体瘤患者的初始安全性和耐受性,并确定1b期使用的推荐剂量。1b期将进一步评估安全性和耐受性,以及初步疗效,并在3个疾病特异性扩展队列中确定ADRX-0706的最佳剂量。
[Translation] This is a two-part study. Phase 1a will include dose escalation of ADRX-0706 to evaluate initial safety and tolerability in selected patients with advanced solid tumors and determine the recommended dose for use in Phase 1b. Phase 1b will further evaluate safety and tolerability, as well as preliminary efficacy, and determine the optimal dose of ADRX-0706 in 3 disease-specific expansion cohorts.
100 Clinical Results associated with Shanghai Defeng Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Shanghai Defeng Pharmaceutical Co., Ltd.
100 Deals associated with Shanghai Defeng Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Shanghai Defeng Pharmaceutical Co., Ltd.